![Bowers_48](https://www.hivplusmag.com/media-library/bowers-48.jpg?id=32703642&width=1200&height=1640)
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study has been following 11 HIV populations in Europe, North America, and Australia since 1999. Last year study researchers reported that there was about a 10% increase risk of heart attacks with protease inhibitors compared to nonnucleoside reverse transcriptase inhibitors. At this year's Conference on Retroviruses and Opportunistic Infections the researchers presented a poster comparing the cardiovascular risk of specific nucleoside drugs. This study identified 517 heart attacks in 33,000 patients over five years. Somewhat unexpectedly there was no increased risk of heart attack with AZT or Zerit despite the drugs' association with lipoatrophy, elevated lipids, and insulin resistance. More surprisingly, the researchers found that the relative risk of heart attack increased by 90% with Ziagen and 49% with Videx. Even more confusing was the fact that this elevated risk happened within the first six months of starting the drugs but did not increase with longer use. Once the drugs were stopped, the increased risks disappeared. Adjusting for other risk factors such as smoking, elevated lipids, and hypertension produced the same results. Because there appears to be no plausible mechanism to explain these results, the investigators made the unusual move to issue a position statement while the full report is being finalized. (Posters are brief 200 - 300 word summaries.) They reminded us that this is an observational report, which cannot prove causality. Only a prospective randomized trial can do that. Next they emphasized that this is a relative, not absolute, risk increase. This means that for someone with a 1% risk (such as a 20-year-old, non-smoking man) the risk increases to only 1.9%. However, in someone with a 20% risk (a 50-year-old man who smokes and has high blood pressure) the risk increase could be substantial These explanations were meant to avoid over-interpretation of the poster data and a knee-jerk reaction to take everyone off Ziagen, which would include stopping treatment with the combination pill Epzicom that contains both Ziagen and Epivir. Some experts question whether a 'channeling bias' occurred in the study, meaning that patients were selected to receive Ziagen based on other subtle criteria we haven't accounted for. And many worry that patients will stop their anti-HIV medications on their own. This concern stems in part from the results of the Strategies for Management of Antiretroviral Therapy (SMART) study that looked at treatment interruptions. That study showed those who interrupted their HIV treatment had an increased risk of heart attack due to a significant rise in inflammatory markers for plaque and clot formation that occurs during treatment breaks. The final caveat was that Viread was not part of the D:A:D study because it had not been on the market long enough when the study began to accrue a significant number of patients taking the medication. The bottom line is that HIVers should talk with their physicians about whether to stay on Ziagen and not unilaterally stop this medication. Equally important is engaging in this conversation presents an ideal time to focus on controlling the much greater heart attack risk factors of smoking, high blood pressure, elevated lipids, and diabetes. Bowers is an HIV specialist and board-certified physician in family practice, and he is a senior partner with Pacific Oaks Medical Group, one of the largest U.S. practices devoted to HIV care, in Beverly Hills, Calif.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Before AIDS, gay artist Rex drew hot men on the prowl — then he disappeared
April 11 2024 3:15 PM
Diets that mimic fasting reverse aging: study
March 07 2024 5:28 PM
PrEP without a prescription now a reality in California
February 06 2024 8:37 PM
Injectable HIV treatment, prevention: Everything you need to know
March 26 2024 3:28 PM
8 dating tips for gay men from a gay therapist
March 21 2024 2:50 PM
Happy national foreskin day!
April 04 2024 1:45 PM
The science behind U=U has been liberating people with HIV for years
June 04 2024 3:31 PM
Scarlet fever: exploring our fascination with blood
March 13 2024 1:47 PM
On Anal Sex Day, crack up with The Bottom's Digest
April 18 2024 10:22 AM
Plus: Featured Video
Latest Stories
Activist and philanthropist Bruce Bastian dies at 76
June 26 2024 1:28 PM
Yes, HIV-positive people can safely breastfeed
June 26 2024 12:59 PM
Exclusive: We kiki with Q from 'RuPaul's Drag Race'
June 24 2024 11:37 AM
Court rules to keep PrEP coverage under Obamacare
June 21 2024 5:42 PM
In honor of Juneteenth 2024, meet The Normal Anomaly
June 19 2024 1:39 PM
What is Juneteenth?
June 19 2024 11:30 AM
As Pride party season begins, the CDC urges mpox vaccinations
May 16 2024 6:52 PM
Advocacy in action with AIDSWatch
May 09 2024 12:30 PM
The Talk: Thriving with HIV
May 08 2024 10:45 AM
The Talk: What HIV isn’t
May 07 2024 10:48 AM
The Talk: Finding balance with HIV
May 06 2024 10:51 AM
Justice Dept plans to reschedule marijuana as a lower-risk drug
May 03 2024 2:40 PM
The Talk: Starting your journey with HIV
May 03 2024 2:00 PM
Why is a mother’s mental health so important? A doctor explains
May 01 2024 1:38 PM
Walmart to close all of its health care clinics
April 30 2024 12:30 PM
Vampire facial spa infected several women with HIV
April 29 2024 7:26 PM